IO Learning

IO Learning IO Learning provides a full range of professional and clinical resources for interventional oncology clinicians.

IO Learning is the Official News Source for the Symposium on Clinical Interventional Oncology. IO Learning is a web-based resource from HMP Communications that seeks to inform readers on the latest advancements in interventional oncologic treatments. It provides an educational forum to increase knowledge and enable multidisciplinary collaboration in this rapidly growing field. IO Learning is desig

ned for all professionals in the interventional oncology field, including interventional radiologists, oncologists, nurse practitioners, physician assistants, nurses, and radiologic technologists. Reflecting the broad spectrum of specialties involved, IO Learning will also address this practice as it relates to referring physician groups in surgery, medical oncology, and radiation therapy. The site features original contributions, clinical reviews, case studies, late-breaking clinical trial results, product information, facility profiles, multimedia, editorial commentary, blogs, and interviews with key opinion leaders. IO Learning is available in web, mobile, and tablet application versions and has a presence on all major social media outlets.

IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patientsIMb...
01/04/2024

IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients
IMbrave050 was designed to evaluate the efficacy of adjuvant atezo + bev in delaying or preventing recurrence in patients with high-risk HCC.
https://okt.to/FOzQeP

Lung Ablation: Year in ReviewRobert Suh, MD, a clinical professor in the Department of Radiological Sciences at the Rona...
01/03/2024

Lung Ablation: Year in Review
Robert Suh, MD, a clinical professor in the Department of Radiological Sciences at the Ronald Reagan UCLA Medical Center, presented a comprehensive overview of the current state of lung ablation during CIO 2023.
https://okt.to/grTbpi

The ACCLAIM Trial: Assessing Microwave Ablation as the Standard of Care for Colorectal Liver MetastasesElena Violari, MD...
01/02/2024

The ACCLAIM Trial: Assessing Microwave Ablation as the Standard of Care for Colorectal Liver Metastases
Elena Violari, MD, interventional radiologist and member of the SIO’s Publications Committee invites Constantinos Sofocleous, MD, interventional radiologist and principal investigator of the ACCLAIM trial, to discuss the study’s origins and provide an update on ACCLAIM, which recently enrolled its first patient.
https://okt.to/kG5lFn

A Case Report of Successful Treatment of Metastatic Liposarcoma with Pulsed Electric FieldsEbstesam Nafie discusses her ...
12/21/2023

A Case Report of Successful Treatment of Metastatic Liposarcoma with Pulsed Electric Fields
Ebstesam Nafie discusses her CIO 2023 abstract, "CIO 2023-24 A Case Report of Successful Treatment of Metastatic Liposarcoma with Pulsed Electric Fields."
https://okt.to/SOCGFc

Palliative Ablation and Kyphoplasty for a Suspected Metastatic FractureHanna Thompson discusses her CIO 2023 abstract, "...
12/20/2023

Palliative Ablation and Kyphoplasty for a Suspected Metastatic Fracture
Hanna Thompson discusses her CIO 2023 abstract, "CIO 2023-30 Palliative Ablation and Kyphoplasty for a Suspected Metastatic Fracture."
https://okt.to/e9uqK2

The Evolving Role of Hepatic Ablation with Dr. Raul UppotRaul Uppot, MD, from Massachusetts General Hospital, delivered ...
12/19/2023

The Evolving Role of Hepatic Ablation with Dr. Raul Uppot
Raul Uppot, MD, from Massachusetts General Hospital, delivered a comprehensive presentation on the dynamic landscape of hepatic ablation during CIO 2023.
https://okt.to/1phUJP

Redefining the ‘Status Quo’ of IORiad Salem, MD, Chief of Vascular and Interventional Radiology in the Department of Rad...
12/18/2023

Redefining the ‘Status Quo’ of IO
Riad Salem, MD, Chief of Vascular and Interventional Radiology in the Department of Radiology at Northwestern Medicine, discusses the future of IO, unique approaches to Y-90, and what's next for the interventional oncology field in 2024.
https://okt.to/sXhdKu

Last chance to sign up for the LIVE webinar, “Evolving Treatment Paradigms in Hepatocellular Carcinoma (HCC) – The Case ...
12/06/2023

Last chance to sign up for the LIVE webinar, “Evolving Treatment Paradigms in Hepatocellular Carcinoma (HCC) – The Case for IR-Med Onc Collaboration.” Don’t miss out: https://okt.to/thIQSK

Don't forget to sign up for the LIVE webinar, “Evolving Treatment Paradigms in Hepatocellular Carcinoma (HCC) – The Case...
12/04/2023

Don't forget to sign up for the LIVE webinar, “Evolving Treatment Paradigms in Hepatocellular Carcinoma (HCC) – The Case for IR-Med Onc Collaboration.” Don’t miss out: https://okt.to/pjtg2l

Learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient care through current and future treatments for HCC in...
11/30/2023

Learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient care through current and future treatments for HCC in this LIVE webinar:
https://okt.to/ol8eUE

Learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient care through current and future treatments for HCC in...
11/27/2023

Learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient care through current and future treatments for HCC in this LIVE webinar:
https://okt.to/iIWqNS

IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients Fa...
11/24/2023

IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients Favorite
IMbrave050 was designed to evaluate the efficacy of adjuvant atezo + bev in delaying or preventing recurrence in patients with high-risk HCC.
https://okt.to/r9uTcE

Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma...
11/23/2023

Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma
In the primary analysis of the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma, STRIDE significantly improved overall survival and demonstrated a durable long-term survival benefit. The authors report an updated 4-year OS analysis of HIMALAYA.
https://okt.to/aDrE6g

Air Embolism Following Lung Biopsy/Ablation and Port Placement: How I Manage ItOleksandra Kutsenko, MD of Red Rock Radio...
11/22/2023

Air Embolism Following Lung Biopsy/Ablation and Port Placement: How I Manage It
Oleksandra Kutsenko, MD of Red Rock Radiology, delivered a presentation at the 2023 Symposium on Clinical Interventional Oncology (CIO) focusing on the significant but rare complication of air embolism associated with lung biopsies and ablations.
https://okt.to/AUliBV

Discussing current and future treatments for HCC, learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient car...
11/22/2023

Discussing current and future treatments for HCC, learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient care. Specific case examples are discussed to provide real world examples of their collaborative approach to HCC treatments.
https://okt.to/3UoQva

Lung Metastases: Locoregional Therapy vs External Beam RadiationModerated by Dr. Steven Yevich from MD Anderson Cancer C...
11/21/2023

Lung Metastases: Locoregional Therapy vs External Beam Radiation
Moderated by Dr. Steven Yevich from MD Anderson Cancer Center, the panel, which included insights from Dr. Robert Suh of UCLA and Dr. Adeel Kaiser from the Miami Cancer Institute, aimed to provide a nuanced understanding of two therapeutic approaches and their relevance in interventional oncology.
https://okt.to/keJtjn

Lung Ablation: Year in ReviewDr. Robert Suh, MD, a Clinical Professor in the Department of Radiological Sciences at the ...
11/20/2023

Lung Ablation: Year in Review
Dr. Robert Suh, MD, a Clinical Professor in the Department of Radiological Sciences at the Ronald Reagan UCLA Medical Center, presented a comprehensive overview of the current state of lung ablation during CIO 2023.
https://okt.to/LrJPA5

Discussing current and future treatments for HCC, learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient car...
11/20/2023

Discussing current and future treatments for HCC, learn how Dr. Liao and Dr. Ahmed partner to ensure optimal patient care. Specific case examples are discussed to provide real world examples of their collaborative approach to HCC treatments.
https://okt.to/eIh3cM

Address

Malvern, PA

Website

Alerts

Be the first to know and let us send you an email when IO Learning posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category